[ad_1]
NICE has recommended interim funding for the NHS in England for Lynparza anticancer treatment of AstraZeneca in the early stages of the disease, as maintenance therapy after a first round of chemotherapy.
The cost-effectiveness reported in the final referral project indicated that the Cancer Fund should reimburse Lynparza (olaparib) in adults with ovarian epithelial cancer , from a fallopian tube or from a high grade peritoneal cancer having reacted to platinum-based first-line chemotherapy.
NICE said the tablet twice a day would be funded as long as the terms of a managed access agreement between AstraZeneca and NHS England would be met.
As usual, AstraZeneca has offered the drug at a discounted price to get funding from NICE.
There was uncertainty in the evidence presented so far by AZ, which NICE was unable to resolve and the profitability monitor expects new data from the ongoing trial on SOLO-1 to confirm the benefits of drug survival.
The estimate is that Lynparza delays the progression of the disease about three years compared with placebo, but the overall survival data is not available at the moment because test were not followed long enough.
Around 700 patients a year should benefit from this decision.
Meindert Boysen, director of the NICE Center for Health Technology Assessment, said, "The availability of olaparib tablets as a maintenance treatment is an important development in cancer management. advanced ovary to BRCA mutation.
"Olaparib is already used for ovarian cancer, but we expect it to be very beneficial if it is used early. It is thought that it could potentially cure the disease in some people if it is administered before the first recurrence.
"We are delighted that the company has entered into a commercial agreement for olaparib, which will make it immediately available to people who currently have an unmet need for maintenance treatment."
Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) that prevents cancerous proteins in cancer cells from repairing damaged DNA in patients with BRCA mutations.
This causes the death of cancer cells but does not affect healthy cells, which do not depend on the PARP protein to survive.
Lynparza will be available from this previous use and may be subject to appeal. The final directives of NICE will be published next month.
In 2016, NICE recommended Lynparza to advanced stages of ovarian cancer, if they had undergone three or more cycles of platinum chemotherapy.
Source link
